A phase 1/2 dose-escalation/expansion study of REGN10597 (anti–PD-1–IL2Rα-IL2) in patients with advanced solid tumors.

Keyphrases

• Dose Escalation 100%
• 2-dose 100%
• Advanced Solid Tumors 100%
• Advanced or Metastatic 80%
• Dosing Schedule 60%
• High-dose interleukin-2 60%
• Pharmacokinetics 40%
• Response Evaluation Criteria in Solid Tumors (RECIST) 40%
• Duration of Response 40%
• Dose Level 40%
• Metastatic Tumor 40%
• Recombinant 40%
• Dose Expansion 40%
• Patient Will 40%
• Lymphocytes 20%
• Antitumor Activity 20%
• Dose-limiting Toxicity 20%
• Cell Death 20%
• Metastatic Renal Cell Carcinoma (mRCC) 20%
• Complete Response 20%
• Serious Adverse Events 20%
• Advanced Melanoma 20%
• Intravenous Infusion 20%
• Vascular Leak 20%
• Disease Progression 20%
• Progression-free Survival 20%
• Interleukin-2 20%
• Efficacy Index 20%
• Soluble interleukin-2 Receptor (sIL-2R) 20%
• Objective Response Rate 20%
• Additional Dose 20%
• Time to Progression 20%
• Metastatic Melanoma 20%
• Reduced Toxicity 20%
• Fusion Protein 20%
• Recommended Phase 2 Dose 20%
• Immunogenicity 20%
• Locally Advanced Cancer 20%
• Locally Advanced 20%
• Tumor Inhibition 20%
• Durable Response 20%
• Severe Toxicity 20%
• Clinical Trial Data 20%
• Disease Control Rate 20%
• Anticancer Immune Response 20%
• Preclinical Animal Models 20%
• Pulmonary Edema 20%
• Time Response 20%
• Best Overall Response 20%
• Clinical Progress 20%
• Two-dose 20%
• Laboratory Abnormalities 20%
• Treatment Discontinuation 20%
• Expansion Cohort 20%
• Trial Enrollment 20%
• Standard-of-care Therapy 20%
• Enhanced Specificity 20%
• Immune Checkpoint Therapy 20%
• Aldesleukin 20%
• Treatment-related Adverse Events 20%
• Safety/tolerability 20%
• First-in-human 20%
• Patient numbers 20%
• Advanced Renal Cell Carcinoma (aRCC) 20%

Medicine and Dentistry

• Solid Malignant Neoplasm 100%
• Interleukin 2 100%
• Drug Megadose 75%
• Cytokine 50%
• Response Evaluation Criteria in Solid Tumors 50%
• Pharmacokinetic 50%
• Adverse Event 50%
• Lymphocyte 25%
• Diseases 25%
• Metastatic Carcinoma 25%
• Clear Cell Renal Cell Carcinoma 25%
• Clinical Trial 25%
• Cell Death 25%
• Receptor 25%
• Intravenous Drug Administration 25%
• Progression Free Survival 25%
• Disease Exacerbation 25%
• Drug Dose Regimen 25%
• Immune Response 25%
• Antineoplastic Activity 25%
• Metastatic Melanoma 25%
• Cancer Inhibition 25%
• Chimeric Protein 25%
• Pulmonary Edema 25%
• Immunogenicity 25%
• Aldesleukin 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Solid Malignant Neoplasm 100%
• Interleukin 2 66%
• Cytokine 33%
• Pharmacokinetic 33%
• Adverse Event 33%
• Diseases 16%
• Renal Cell Carcinoma 16%
• Antitumor Activity 16%
• Clinical Trial 16%
• Mouse Model 16%
• Receptor 16%
• Syndrome 16%
• Progression Free Survival 16%
• Disease Exacerbation 16%
• Tolerability 16%
• Cancer Inhibition 16%
• Metastatic Melanoma 16%
• Chimeric Protein 16%
• Lung Edema 16%
• Immunogenicity 16%
• Aldesleukin 16%